Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the Approved for use through 3/31/2007. OMB 0651-0021

U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US)**

ATTORNEY'S DOCKET NUMBER 21546YP

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DA 29 September 2004 03 October 2003 PCT/US2004/032009 TITLE OF INVENTION BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S APPLICANT(S) FOR DO/EO/US Philippe G. Nantermet, Hemaka Anthony Rajapakse and Harold G. Selnick Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must 3. include items (5), (6), (9) and (21) indicated below. The US has been elected (PCT Article 31). A copy of the International Application as filed [35 U.S.C. 371(c)(2)] a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. X is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto b. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)]. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)]. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)]. Items 11 to 20 below concern other document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 18. A second copy of the published International Application under 35 U.S.C.154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4). 20. Other items or information:

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DQ/EQ/US)Concerning a Submission Under 35 U.S.C. 371"

Approved for use through 3/31/2007. OMB 0651-0021.

U.S. APPLICATION N	O. (If kno	own, see 37 CF	R 1.5)	INTERN	ATIONAL APPLICATION NO.			ATTORNEY'S DOC	KET NUMBER	
				PCT/US	32004/032009			21546YP		
Translig Till safe submitted								CALCULATIONS	PTO USE ONLY	
21. Basic frat	ional fee						\$300	\$300.00		
22. Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report										
If the written opinion prepared by IPEA/US	prepared									
prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)								\$200.00		
23. X Search fee	•									
If the written opinion IPEA/US indicates all										
Search fee [37 CFR 1.	.445(a)(2									
International Searching Authority								\$100.00		
previously communicated to the US by the IB										
All other situations\$500										
TOTAL OF 21, 22 and 23= \$600.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or										
computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets	Extra	Sheets			dditional 50 or fraction to a whole number)		RATE			
- 100 =	0	/50	0		0	X	\$250.00	\$0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].										
CLAIMS	1.492(NUMBER	FILED		NUMBER EXTRA		RATE			
Total Claims		19		- 20 =	0		\$50.00	\$0.00		
Independent Claims		1		- 3 =	0	X	\$200.00	\$0.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00										
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) =								\$600.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)].										
TOTAL NATIONAL FEE								\$600.00		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.										
TOTAL FEES ENCLOSED =							=	\$600.00	-	
	_		* ***					Amount to be		
								refunded:		
								Amount to be charged:		
a. A check in the amount of \$ to cover the above fees is enclosed.										
b. Please charge my Deposit Account No. 13-2755 in the amount of \$600.00 to cover the above fees.										
A duplicate copy of this sheet is enclosed. c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any										
overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.										
SEND ALL CORRESPONDENCE TO:										
Customer No. 000210										
MERCK & CO., INC.										
Patent Department, RY60-30										
P.O. Box 2000 126 East Lincoln Avenue										
Rahway, New Jersey 07065-0970 John C. Todaro						Todo-o				
	-				 -	am C.	1 OUAFO			
DATE: March 23, 2006										
PHONE #: (732) 594-0125						36,036 REGISTRATION NUMBER				

į

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"
Approved for use through 3/31/2007. OMB 0651-0021

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	21546YP				
International Appln No.:	PCT/US2004/032009				
International Filing Date:	29 September 2004				
Priority Date:	03 October 2003				
Title:	BENZYLETHER AND BENZYLAMINO				

Inventors:

Philippe G. Nantermet, Hemaka Anthony Rajapakse and

BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Harold G. Selnick

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT March 23,2006

EL989585393US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY Kathy Cluthousle DATE 3-23-06